NEEDHAM, MA--(Marketwired - June 21, 2016) - Cambridge Healthtech Institute, a division of Cambridge Innovation Institute, is pleased to release the plenary session details for the eighth annual The Bioprocessing Summit to be held August 15-19, 2016 at the Westin Waterfront, Boston, MA. Bristol-Myers Squibb's VP of Process Sciences, Morrey Atkinson, will open the session with a presentation entitled "Challenges Associated with Biomanufacturing of Evolving Portfolios." The accelerating pace of biological product development and high rate of technology advancement is causing shifts in biomanufacturing. This talk will highlight how the biopharma industry is being compelled to match this change with increased flexibility. From clinical supplies to late life-cycle commercial production, demand for innovation and creativity has never been greater, particularly to reliably supply transformational medicines such as the new immuno-oncology products.
In the second part of the plenary session, Biogen's VP of Next Generation Manufacturing, Craig Beasley will present on "Next-Generation Processes, Technologies and Operations." A critical step in meeting the demand of biologic production worldwide involves implementing disruptive manufacturing technologies, processes and capabilities. This talk will evaluate Biogen's new manufacturing site in Switzerland, due to go online in 2019, including the new processes, operational models and technologies being adopted to drive value through innovation and deliver new medicines in areas such as Alzheimer's. The plenary session will be moderated by GEN's Editor-in-Chief, John Sterling.
"The Bioprocessing Summit is again gathering together bioprocess professionals in Boston to share practical solutions for today's bioprocess challenges," states Mary Ruberry, Cambridge Healthtech Institute's Senior Conference Director. "The biopharma industry continues to change and grow, and greater demands are put on production output as more biologics head into manufacturing. Meeting this growing demand becomes even more challenging when handling complex products. This year's Summit explores how to keep up with the production demand and prepare for next-generation biologics."
The Bioprocessing Summit, entering its eighth year, convenes more than 1,000 international bioprocess professionals. The event features 16 distinct meetings ranging from cell line development and ensuring quality, to formulation, analytical development, continuous processing, purification, viral clearance and safety, and bioproduction. New programming in 2016 will continue to expand the scope of the event and includes weeklong programming on cell and gene therapy production, and a meeting on manufacturing and CMC strategies for biologics. Along with the conferences, the Summit also includes Short Courses and Training Seminars that provide in-depth coverage of critical bioprocess topics.
Full program details can be found at www.bioprocessingsummit.com. Advance registration rates apply and are available until July 15.
Members of the media are encouraged to attend. Please contact Lisa Scimemi at firstname.lastname@example.org to apply for a press pass.
About Cambridge Healthtech Institute (www.healthtech.com)
Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Preclinical Congress, The Bioprocessing Summit, Next Generation Dx Summit and Discovery on Target. CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, Knowledge Foundation, Bio-IT World, Clinical Informatics News and Diagnostics World.